JP2021505540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505540A5 JP2021505540A5 JP2020529281A JP2020529281A JP2021505540A5 JP 2021505540 A5 JP2021505540 A5 JP 2021505540A5 JP 2020529281 A JP2020529281 A JP 2020529281A JP 2020529281 A JP2020529281 A JP 2020529281A JP 2021505540 A5 JP2021505540 A5 JP 2021505540A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- pharmaceutical composition
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023173950A JP2024001187A (ja) | 2017-12-01 | 2023-10-06 | 乳がんの処置のためのヒト化抗ｌｉｖ１抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593660P | 2017-12-01 | 2017-12-01 | |
| US62/593,660 | 2017-12-01 | ||
| PCT/US2018/063425 WO2019109007A1 (en) | 2017-12-01 | 2018-11-30 | Humanized anti-liv1 antibodies for the treatment of breast cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023173950A Division JP2024001187A (ja) | 2017-12-01 | 2023-10-06 | 乳がんの処置のためのヒト化抗ｌｉｖ１抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021505540A JP2021505540A (ja) | 2021-02-18 |
| JP2021505540A5 true JP2021505540A5 (https=) | 2022-01-11 |
Family
ID=64746653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529281A Pending JP2021505540A (ja) | 2017-12-01 | 2018-11-30 | 乳がんの処置のためのヒト化抗ｌｉｖ１抗体 |
| JP2023173950A Withdrawn JP2024001187A (ja) | 2017-12-01 | 2023-10-06 | 乳がんの処置のためのヒト化抗ｌｉｖ１抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023173950A Withdrawn JP2024001187A (ja) | 2017-12-01 | 2023-10-06 | 乳がんの処置のためのヒト化抗ｌｉｖ１抗体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20200283540A1 (https=) |
| EP (1) | EP3717518A1 (https=) |
| JP (2) | JP2021505540A (https=) |
| KR (1) | KR20200090838A (https=) |
| CN (1) | CN111757892A (https=) |
| AU (1) | AU2018375182A1 (https=) |
| BR (1) | BR112020010937A2 (https=) |
| CA (1) | CA3084495A1 (https=) |
| EA (1) | EA202091360A1 (https=) |
| IL (1) | IL274766A (https=) |
| MA (1) | MA50943A (https=) |
| MX (1) | MX2020005640A (https=) |
| SG (1) | SG11202004751TA (https=) |
| WO (1) | WO2019109007A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2648752B1 (en) | 2010-12-06 | 2017-02-15 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
| MX2018010847A (es) | 2016-03-15 | 2019-07-04 | Seattle Genetics Inc | Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico. |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| GB201908208D0 (en) * | 2019-06-10 | 2019-07-24 | Univ College Cardiff Consultants Ltd | An anti-mitotic agent |
| AU2020318975A1 (en) * | 2019-07-22 | 2022-03-17 | Seagen Inc. | Humanized anti-LIV1 antibodies for the treatment of cancer |
| KR20220114002A (ko) * | 2019-12-09 | 2022-08-17 | 씨젠 인크. | Liv1-adc 및 pd-1 길항제를 사용하는 병용 요법 |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| CN119317646A (zh) * | 2022-06-16 | 2025-01-14 | 山东博安生物技术股份有限公司 | 抗liv-1抗体及其药物偶联物 |
| IL322565A (en) | 2023-02-07 | 2025-10-01 | Lanova Medicines Ltd | Antibodies targeting liv-1 and their uses |
| AU2024235054A1 (en) * | 2023-03-15 | 2025-10-02 | BioRay Pharmaceutical Co., Ltd. | Anti-liv-1 antibody and anti-liv-1 antibody-drug conjugate, and pharmaceutical use thereof |
| WO2025146137A1 (zh) * | 2024-01-05 | 2025-07-10 | 海南先声再明医药股份有限公司 | 抗liv-1抗体药物偶联物及其用途 |
| CN120040587B (zh) * | 2025-04-27 | 2025-08-08 | 上海宏成药业有限公司 | 抗liv-1抗体或其抗原结合片段及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| DK0871490T3 (da) | 1995-12-22 | 2003-07-07 | Bristol Myers Squibb Co | Forgrenede hydrazonlinkere |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| WO2004067564A2 (en) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| TW200813231A (en) * | 2006-04-13 | 2008-03-16 | Novartis Vaccines & Diagnostic | Methods of treating, diagnosing or detecting cancer |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| EP2648752B1 (en) * | 2010-12-06 | 2017-02-15 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
| MX2014013763A (es) * | 2012-05-11 | 2015-02-20 | Merrimack Pharmaceuticals Inc | Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer. |
| US9492566B2 (en) * | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| WO2015175533A2 (en) * | 2014-05-13 | 2015-11-19 | Immunogen, Inc. | Anti-cd37 immunoconjugate dosing regimens |
| MX2018010847A (es) * | 2016-03-15 | 2019-07-04 | Seattle Genetics Inc | Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico. |
-
2018
- 2018-11-30 SG SG11202004751TA patent/SG11202004751TA/en unknown
- 2018-11-30 KR KR1020207017651A patent/KR20200090838A/ko not_active Abandoned
- 2018-11-30 MA MA050943A patent/MA50943A/fr unknown
- 2018-11-30 BR BR112020010937-1A patent/BR112020010937A2/pt not_active IP Right Cessation
- 2018-11-30 CN CN201880077514.3A patent/CN111757892A/zh active Pending
- 2018-11-30 EA EA202091360A patent/EA202091360A1/ru unknown
- 2018-11-30 EP EP18822563.5A patent/EP3717518A1/en not_active Withdrawn
- 2018-11-30 WO PCT/US2018/063425 patent/WO2019109007A1/en not_active Ceased
- 2018-11-30 AU AU2018375182A patent/AU2018375182A1/en not_active Abandoned
- 2018-11-30 CA CA3084495A patent/CA3084495A1/en active Pending
- 2018-11-30 MX MX2020005640A patent/MX2020005640A/es unknown
- 2018-11-30 JP JP2020529281A patent/JP2021505540A/ja active Pending
- 2018-11-30 US US16/768,020 patent/US20200283540A1/en not_active Abandoned
-
2020
- 2020-05-19 IL IL274766A patent/IL274766A/en unknown
-
2023
- 2023-03-07 US US18/179,560 patent/US20240076402A1/en not_active Abandoned
- 2023-10-06 JP JP2023173950A patent/JP2024001187A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505540A5 (https=) | ||
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| JP2021063088A5 (https=) | ||
| JP2019031565A5 (https=) | ||
| KR101155294B1 (ko) | 면역특이적으로 ＢＬｙＳ에 결합하는 항체 | |
| JP2021100937A5 (https=) | ||
| JP2013543498A5 (https=) | ||
| JP2021519076A5 (https=) | ||
| JP2016528247A5 (https=) | ||
| JP2019031567A5 (https=) | ||
| JP2008528638A5 (https=) | ||
| JP2020002172A5 (https=) | ||
| JP2020509027A5 (https=) | ||
| RU2012133522A (ru) | Новое применение соединений ил-1 бета | |
| JP2016502504A5 (https=) | ||
| JP2014114288A5 (https=) | ||
| JP2015534579A5 (https=) | ||
| MX2020002429A (es) | Compuestos para reducir la viscosidad de las formulaciones biologicas. | |
| JP2018529661A5 (https=) | ||
| JP2005506331A5 (https=) | ||
| JP2019520316A5 (https=) | ||
| JP2021520393A5 (https=) | ||
| JP2019521156A5 (https=) | ||
| JP2018512402A5 (https=) | ||
| JP2018530574A5 (https=) |